Connecting Type 1 and Type 2 Diabetes through Innate Immunity

  1. Ajay Chawla2
  1. 1Department of Pathology, Stanford University School of Medicine, Stanford, California 94305
  2. 2Cardiovascular Research Institute, Department of Physiology, and Department of Medicine, University of California, San Francisco, San Francisco, California 94158
  1. Correspondence: ajay.chawla{at}ucsf.edu

Abstract

The escalating epidemic of obesity has driven the prevalence of both type 1 and 2 diabetes mellitus to historically high levels. Chronic low-grade inflammation, which is present in both type 1 and type 2 diabetics, contributes to the pathogenesis of insulin resistance. The accumulation of activated innate immune cells in metabolic tissues results in release of inflammatory mediators, in particular, IL-1β and TNFα, which promote systemic insulin resistance and β-cell damage. In this article, we discuss the central role of innate immunity and, in particular, the macrophage in insulin sensitivity and resistance, β-cell damage, and autoimmune insulitis. We conclude with a discussion of the therapeutic implications of this integrated understanding of diabetic pathology.

Also in this Collection

    | Table of Contents

    Richard Sever interviews Joan Brugge